Project Grant R41AI186830
Award Date
8/6/24
Completion Date
2/1/25
Dollars Obligated
$562K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Abwiz Bio Inc. (NL12MYXYBMA1)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $294,583 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Mapp Biopharmaceutical, Inc., a San Diego-based biotechnology company. The funding supports the development of a novel, cost-effective multispecific therapeutic for dengue, a major global health concern. Mapp Biopharmaceutical is creating a tri-specific antibody fragment molecule designed to enhance therapeutic efficacy...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $230,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute. The purpose of this 2-year grant, with a start date of January 23, 2025, is to evaluate recently discovered neuraminidase broadly neutralizing antibodies (NA BnAbs) for their potential use in a universal influenza vaccine. The research will assess factors such as precursor frequency,...
This Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), aims to develop a novel vaccine candidate that stimulates immune protection against multi-drug resistant Acinetobacter baumannii (MDR-AB). The $288,360 award to Biological Mimetics, Inc., a biotechnology firm in Frederick, Maryland, supports a Phase I project to: (1) identify and characterize key immunogenic...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $835,137 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to the Icahn School of Medicine at Mount Sinai. The goal of this 5-year project is to develop a repository of 50 monoclonal antibodies (25 anti-hamster and 25 anti-guinea pig) that can be used to study immune and inflammatory responses in hamster and guinea pig animal models, which are important for researching infectious...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, has awarded a $300,156 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Intact Genomics Inc., a minority-owned small business. The funding will support research to identify new antifungal compounds with novel mechanisms of action from filamentous fungi. The key objectives are to demonstrate the use of Aspergillus nidulans as a...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded Scribe Biosciences, Inc. a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a high-throughput antibody discovery platform against cell membrane-bound proteins. Scribe Biosciences, a for-profit company specializing in microfluidics and biomedical engineering, will utilize its proprietary Microenvironment on Demand (MOD) technology to assemble over 100,000 single-cell...
This Project Grant award of $1,000,000 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports the development of Partillion Bioscience Corp's advanced antibody discovery workflows. The funding aims to enhance their specialized hydrogel microparticle technology called "nanovials" to enable ultra high-throughput screening and functional assessment of single B cells and antibody-secreting cells. This is expected...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $867,563 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Rockefeller University. The grant supports the development of a pioneering class of nanobodies engineered from llama immune systems to provide comprehensive protection against all betacoronaviruses, including SARS-CoV-1, MERS-CoV, and SARS-CoV-2. Key goals include strategically expanding nanobody repertoires, identifying...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,995 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Xiretsa Inc., a minority-owned small business located in Santa Barbara, CA. The grant will fund the development of a novel class of antimicrobial compounds called Anti-Infective Conjugated Electrolytes (ACEs) that target the bacterial cell membrane to address the growing threat of antimicrobial resistance. The project...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $300,000 to Emmune Inc., a small business in Cambridge, MA, to conduct pre-clinical IND-enabling studies for their ECD4-IG recombinant protein therapeutic for HIV. The goal is to generate data to support an Investigational New Drug (IND) application to the FDA and enable a Phase 1 clinical trial of this long-acting...